Information for CJC 1295 w DAC
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that increases plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). DAC is an additive moiety that prolongs the plasma half-life of CJC-1295.
Research Certificates of Analysis
6.98mg
Task #42379
Batch #04152024
04/23/2024
GMP Certificates of Analysis
5.2mg
Batch #PKCJCDAC5924
09/10/2024
CJC 1295 w DAC Peptide Structure
Source: Oxford Academic
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842
What Is CJC 1295 w DAC?
Stimulates production of growth hormone1,2,3
Increases concentration of Insulin-like growth factor2,3
Drug affinity complex (DAC) extends half life up to 8 days2
Upregulates beta hemoglobin4
Enact trophic effects in pituitary gland5
Research Studies
- Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., Van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human Growth Hormone-Releasing Factor (HGRF)1–29-Albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a Long-Lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
- Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and Insulin-Like growth Factor I secretion by CJC-1295, a Long-Acting analog of GH-Releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
- Ionescu, M., & Frohman, L. A. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
- Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471–477. https://doi.org/10.1016/j.ghir.2009.03.001
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Endocrinology and Metabolism/American Journal of Physiology: Endocrinology and Metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006
Product Usage
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
